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An autophagy-enhancing drug promotes degradation of mutant
alpha1-antitrypsin Z and reduces hepatic ﬁbrosis. Hidvegi T,
Ewing M, Hale P, Dippold C, Beckett C, Kemp C, Maurice N, Muk-
herjee A, Goldbach C, Watkins S, Michalopoulos G, Perlmutter
DH. Science 2010;329(5988):229–32. Abstract reprinted with
permission from the AAAS.
http://www.ncbi.nlm.nih.gov/pubmed/20522742
Abstract: In the classical form of alpha1-antitrypsin (AT) deﬁciency,
a point mutation in AT alters the folding of a liver-derived secretory
glycoprotein and renders it aggregation-prone. In addition to
decreased serum concentrations of AT, the disorder is characterized
by accumulation of the mutant alpha1-antitrypsin Z (ATZ) variant
inside cells, causing hepatic ﬁbrosis and/or carcinogenesis by a
gain-of-toxic function mechanism. The proteasomal and autophagic
pathways are known to mediate degradation of ATZ. Here we show
that the autophagy-enhancing drug CBZ (CBZ) decreased the hepatic
load of ATZ and hepatic ﬁbrosis in a mouse model of AT deﬁciency-
associated liver disease. These results provide a basis for testing
CBZ, which has an extensive clinical safety proﬁle, in patients with
AT deﬁciency and also provides a proof of principle for therapeutic
use of autophagy enhancers.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Toxic accumulation of misfolded protein aggregates is a common
feature of various disorders (proteinopathies) including (i) hepatic
ﬁbrosis and/or carcinogenesis caused by alpha1-antitrypsin (AT)
deﬁciency [1], (ii) cystic ﬁbrosis caused by cystic ﬁbrosis transmem-
brane conductance regulator (CFTR) [2], and (iii) neurodegenerative
diseases [3]. In Mendelian forms of these diseases, the mutations
generally confer novel toxic functions to the proteins involved.
Thus, one potential strategy for dealing with thesemutant proteins
would be to boost their degradation. This could be achieved by up-
regulatingmacroautophagy (hereafter called autophagy), by which
intracellular components are sequestered and delivered to lyso-Journal of Hepatology 20
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E-mail address: mehrpourmaryam@yahoo.fr (M. Mehrpour).suggest that basal autophagy, the routine method by which the
cytosol is cleared of protein aggregates and damaged organelles,
is in fact crucial for maintaining healthy cells [5–7].
AT is a plasma serine protease inhibitor belonging to the serpin
superfamily. It protects tissues against enzymes produced by
inﬂammatory cells, especially neutrophil elastase, a protease that
can degrade all constituents of the pulmonary connective tissue
matrix. AT is primarily synthesized in hepatocytes. It is inserted
into the endoplasmic reticulum (ER), where only the correctly-
folded, soluble monomeric form of AT is secreted through the ER
membrane and Golgi complex to be released from the cell
(Fig. 1). Misfolded monomeric forms of AT are extracted into the
cytoplasm and degraded via the proteasome pathways. Conse-
quently, the circulating concentration of AT is low, leaving elastase
free to breakdown elastin, resulting in respiratory complications
such as pulmonary emphysema, or chronic obstructive pulmonary
disease in adults, by a loss-of-function mechanism.
A point mutation (lysine for glutamate 342) known as ATZ can
lead to non-functional proteins that can polymerize and accumu-
late in the ER. This accumulation in the ER causes inﬂammation of
the liver (infantile hepatic cirrhosis), and carcinogenesis by a
gain-of-toxic function mechanism. Thus, AT deﬁciency can be
viewed as a prototype, a naturally-occurring form of the ‘‘ER
stress’’ state. In terms of cellular response pathways, accumula-
tion of ATZ in the ER speciﬁcally activates the autophagy
response, but not the unfolded-protein response.
Because the autophagy response is involved in both the deg-
radation of ATZ and the cellular response to the accumulation
of ATZ in the ER, it is interesting to consider the possibility that
drugs enhancing autophagy could help to attenuate the hepato-
toxicity associated with hepatic ﬁbrosis and/or carcinogenesis
caused by ATZ. In a study published in January in Science [8],
Perlmutter’s team addressed this issue using an elegant strat-
egy. They selected carbamazepine (CBZ) from a list of drugs
recently shown to enhance the mTOR-independent autophagic
degradation of aggregation-prone proteins [9]. They showed
how CBZ, a drug currently used as an anticonvulsant and a
mood stabilizer, could have beneﬁcial effects in genetic liver
disease.
Results from cell-based studies suggest that CBZ produces its
effects by changing the rate of intracellular degradation of insol-
uble ATZ, but that does not alter the fate of wild type AT. This
change occurs by increasing the stimulation of autophagy. CBZ
was earlier reported to enhance in neuron the clearance of aggre-
gation-prone protein by mTOR-independent and inositol-
phosphate dependent autophagy (Fig. 1) [3]. However, the role11 vol. 54 j 1066–1068
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Fig. 1. Autophagy as a protective pathway in proteinopathies. The relevant proteins are primarily synthesized and inserted into the ER. Only the correctly-folded soluble
monomeric forms are then released from the cell surface. Soluble monomers are transported from the ER into the cytoplasm where they are degraded by the proteasome.
Toxic accumulations of mutant misfolded protein aggregates are degraded by autophagy. Chemical induction of autophagy by enhancers (for instance CBZ) triggers cellular
signaling pathways (see Box), leading to the formation of phagophores, which expand and engulf portions of the cytoplasm, forming double-membrane vesicles known as
autophagosomes. The autophagosomes then fuse with lysosomes to form autolysosomes, after which their contents are degraded. Enhancing the autophagic clearance of
mutant aggregate-prone proteins, for instance ATZ, results in a reduction of mutant protein aggregates and in toxicity, which has demonstrated a protective effect in several
proteinopathy models. Box: Autophagy is a cytoprotective mechanism which is regulated by mTOR-dependent (sensitive to rapamycin) and mTOR-independent pathways
(sensitive to CBZ).
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of an mTOR-dependent pathway sensitive to rapamycin cannot
be totally excluded in the inhibition of ATZ accumulation
via polymerized conformation, as reported by Teckman’s team
[10].
The authors went onto determine whether the effects of CBZ
are speciﬁc to ATZ. They have investigated its effect on the
disposal of a variant form of AT, known as AT Saar, which accu-
mulates in ER without aggregating, and is predominantly
degraded via a proteasomal mechanism. CBZ degraded ATZ and
AT Saar in an identical manner, suggesting that CBZ also has an
effect on the proteasome (Fig. 1).
Next, the authors examined the effect of CBZ on the hepatic
load of ATZ, in a mouse model of liver disease associated with
AT deﬁciency. Administration of CBZ decreased the levels of total,
insoluble and soluble ATZ in the liver, and also of the intrahepat-
ocytic ATZ-containing globules, whereas it increased hepatic
autophagosomes. In models of hepatic ﬁbrosis, CBZ reduced both
ﬁbrosis and liver damage.
Although there is strong evidence implicating the insoluble
polymers, the available data fall short of establishing the identity
of the toxic species. It has recently been shown that in cystic
ﬁbrosis, defective CFTR induces aggresome formation by inhibit-
ing ROS-mediated autophagy [7].
Findings reported by Hidvegi et al. have provided the rationale
for studies on CBZ in patients with AT deﬁciency, and conﬁrmed
that autophagy enhancers could be used to ﬁght protein overload
in genetic diseases. It would be interesting to ﬁnd out whether
the combination of CBZ with mTOR-dependent autophagy induc-
ers results in a greater up-regulation of autophagy and clearance
of ATZ [3]. The question is now whether this approach will be
useful for treating genetics diseases associated with aggrega-
tion-prone protein in human.1068 Journal of Hepatology 2011Conﬂict of interest
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